|Table of Contents|

Value of IMTF prediction model in 74 patients with chronic myelogenous leukemia treated with first-line imatinib in a single center

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 10
Page:
1880-1886
Research Field:
Publishing date:

Info

Title:
Value of IMTF prediction model in 74 patients with chronic myelogenous leukemia treated with first-line imatinib in a single center
Author(s):
DUAN Xiaohui; GAO Shan; WANG Jianhong; DONG Hongjuan; FENG Juan; TANG Hailong; LYU Yao; WANG Shixiong; WU Zhentian; ZHANG Tao; GAO Guangxun; LIANG Rong
Department of Hematology,the First Affiliated Hospital of Air Force Medical University,Shaanxi Xi'an 710032,China.
Keywords:
IMTF; chronic myelogenous leukemia; imatinib; predictive value
PACS:
R733.72
DOI:
10.3969/j.issn.1672-4992.2023.10.020
Abstract:
Objective:To investigate the predictive value of imatinib-therapy failure (IMTF) prediction model in complete cytogenetic response （CCyR）,major molecular response （MMR）,molecular response 4.0 （MR4.0),molecular response 4.5 （MR4.5) and failure-free survival （FFS） of patients with different prognostic stratifications,and to analyse the significance of early optimal response on long-term sustained deep molecular response (DMR).Methods:Clinical and follow-up data were collected for analyzing the prognosis in 185 patients with Ph-positive chronic myelogenous leukemia (CML) in our centre from 2018 to 2021.Results:Among the 185 patients,74 patients received regular treatment and regular monitoring.The median age of onset was 45.5 (11~78) years old.68.9% (51/74) patients were males.64.9% (48/74) patients had splenomegaly.According to the Sokal score,there were 45 (60.8%) patients in low risk,while there were 26 (35.1%) patients in intermediate risk,and 3 (4.1%) patients in high risk.FFS of patients in low and intermediate risk group was significantly better than those in high risk group.According to the ELTS score,there were 15 (20.3%) patients in low risk,while there were 31 (41.9%) patients in intermediate risk,and 28 (37.8%) patients in high risk.CCyR,MMR,MR4.0,MR4.5,FFS were not statistically significant in patients with different prognostic stratifications.According to the IMTF score,there were 4 (5.4%) patients in very low risk,10 (13.5%) patients in low risk,23 (31.1%) patients in intermediate risk,26 (35.1%) patients in high risk,and 11 (14.9%) patients in very high risk.In FFS,the prognosis of patients in the very high risk group was poor.59.4% (41/69) patients had fusion gene <10% at 3 months.There was a significant difference in DMR at 2 and 5 years between patients who achieved an early optimal response at 3 months and those who did not.There was no difference in DMR at 2 and 5 years between patients who achieved an optimal response at 6 and 12 months and those who did not.Conclusion:Compared with the traditional score,the IMTF model can more accurately screen the potentially very high-risk patients,better predict FFS and further distinguish the patients who may have imatinib failure,guide the selection of TKI drugs and contribute to the long-term sustained DMR.

References:

[1] HU Y,LI Q,HOU M,et al.Magnitude and temporal trend of the chronic myeloid leukemia:on the basis of the global burden of disease study 2019［J］.JCO Glob Oncol,2021,7:1429-1441.
[2] JABBOUR E,KANTARJIAN H.Chronic myeloid leukemia:2022 update on diagnosis,therapy,and monitoring［J］.Am J Hematol,2022,97(9):1236-1256.
[3] HOCHHAUS A,LARSON RA,GUILHOT F,et al.Long-term outcomes of imatinib treatment for chronic myeloid leukemia［J］.N Engl J Med,2017,376(10):917-927.
[4] SPECCHIA G,PREGNO P,BRECCIA M,et al.Prognostic factors for overall survival in chronic myeloid leukemia patients:a multicentric cohort study by the Italian CML GIMEMA network［J］.Front Oncol,2021,11:739171.
[5]ZHANG XS,GALE RP,ZHANG MJ,et al.A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy［J］.Leukemia,2022,36(5):1336-1342.
[6] 中华医学会血液学分会.慢性髓性白血病中国诊断与治疗指南（2020年版）［J］.中华血液学杂志,2020,41(05):353-364. Society of Hematology,Chinese Medical Association.Chinese guidelines for diagnosis and treatment of chronic myeloid leukemia (2020 edition)［J］.Chin J Hematology,2020,41(05):353-364.
[7] SOKAL JE,COX EB,BACCARANI MI,et al.Prognostic discrimination in "goodrisk"chronic granulocytic leukemia［J］.Blood,1984,63(4):789-799.
[8] PFIRRMANN M,BACCARANI M,SAUSSELE S,et al.Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia［J］.Leukemia,2016,30(1):48-56.
[9]PFIRRMANN M,CLARK RE,PREJZNER W,et al.The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia［J］.Leukemia,2020,34(8):2138-2149.
[10]贾茜婷,毛建平,薛连国,等.不同评分系统评估慢性粒细胞白血病患者预后的比较［J］.中国肿瘤临床,2019,46(24):1265-1270. JIA QT,MAO JP,XUE LG,et al.Comparison of different scoring systems in evaluating the prognosis of patients with chronic myelogenous leukemia［J］.Chin J Cancer Clin,2019,46(24):1265-1270.
[11] ZHANG XS,GALE RP,HUANG XJ,et al.Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors［J］.Leukemia,2022,36(2):482-491.
[12] SPECCHIA G,PREGNO P,BRECCIA M,et al.Prognostic factors for overall survival in chronic myeloid leukemia patients:a multicentric cohort study by the Italian CML GIMEMA Network［J］.Front Oncol,2021,11:739171.
[13] FABER E,KUBA A,ZAPLETALOVA J,et al.Interferon-alpha in chronic myeloid leukemia revisited:a long-term retrospective study in Central and Northern Moravia［J］.Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub,2013,157(3):248-256.
[14] SANT M,MINICOZZI P,MOUNIER M,et al.Survival for haematological malignancies in europe between 1997 and 2008 by region and age:results of eurocare-5,a population-based study［J］.Lancet Oncol,2014,15:931-942.
[15] ZHANG XS,QIN YZ,LAI YY,et al.Combination of socio-demographic and clinical co-variates for predicting treatment responses and outcomes in patients with chronic myeloid leukemia in the chronic phase［J］.Chin J Hematol,2022,43(1):54-62.
[16] LIPTON JH,BRMMENDORF TH,GAMBACORTI-PASSERINI C,et al.Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia-What to look for when treatment-free remission is not an option［J］.Blood Rev,2022,56:100968.
[17] 中华医学会血液学分会实验诊断学组,中国慢性髓性白血病联盟专家组.中国慢性髓性白血病诊疗监测规范(2014年版)［J］.中华血液学杂志,2014,35(8):781-784. Chinese Society of Hematology,Chinese Medical Association,Chinese CML Committee.Guideline for the diagnosis and management in the disease monitoring of patients with chronic myeloid leukemia in China (2014)［J］.Chin J Hematology,2014,35(8):781-784.
[18] MARMOT M.Fair society,healthy lives.The Marmot review.Strategic review of health inequalities in England post-2010［J］.BMC Public Health,2015,15:662.

Memo

Memo:
National Natural Science Foundation of China(No.8136064）；国家自然科学基金（编号：8136064）；西京医院学科助推计划项目（编号：XJZT18ML81，XJZT18MDT20，XJZT19Z28，XJZT18ML80，XJZT21CZ07）；研究生创新实践能力提升项目（编号：ZG023）
Last Update: 1900-01-01